Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.
暂无分享,去创建一个
Jong Hun Kim | B. S. Ye | J. Jeong | H. Shin | S. Choi | K. Park | Eun-Joo Kim | H. Han | K. Park | J. Im | Tae Eun Kim | Saeromi Kim | S. A. Park | Dong Hyun Lee | Hyeon-Jun Kim
[1] H. Shin,et al. The Correlation Study between Plasma Aβ Proteins and Cerebrospinal Fluid Alzheimer's Disease Biomarkers , 2016, Dementia and neurocognitive disorders.
[2] P. Wolf,et al. Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study , 2015, Alzheimer's & Dementia.
[3] Tao Wang,et al. The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease , 2014, International journal of geriatric psychiatry.
[4] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[5] D. Na,et al. A new classification system for ischemia using a combination of deep and periventricular white matter hyperintensities. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[6] C. Jack,et al. Biomarker Modeling of Alzheimer’s Disease , 2013, Neuron.
[7] J. Williamson,et al. The Demographic and Medical Correlates of Plasma A&bgr;40 and A&bgr;42 , 2013, Alzheimer disease and associated disorders.
[8] J. Trojanowski,et al. Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker , 2013, Alzheimer's Research & Therapy.
[9] D. Na,et al. Preliminary Study for a Multicenter Study of Alzheimer's Disease Cerebrospinal Fluid Biomarkers , 2013 .
[10] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[11] M. Mintun,et al. β-amyloid dynamics in human plasma. , 2012, Archives of neurology.
[12] H. Vanderstichele,et al. Potential sources of interference on Abeta immunoassays in biological samples , 2012, Alzheimer's Research & Therapy.
[13] Deborah Blacker,et al. Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. , 2012, Archives of neurology.
[14] F. Crawford,et al. A Multifaceted Role for apoE in the Clearance of Beta-Amyloid across the Blood-Brain Barrier , 2012, Neurodegenerative Diseases.
[15] P. Scheltens,et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[16] R. Mayeux,et al. Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants , 2011, Neurobiology of Aging.
[17] D. Neary,et al. TDP-43 pathological changes in early onset familial and sporadic Alzheimer’s disease, late onset Alzheimer’s disease and Down’s Syndrome: association with age, hippocampal sclerosis and clinical phenotype , 2011, Acta Neuropathologica.
[18] C. Jack,et al. Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI , 2011, Acta Neuropathologica.
[19] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[20] R. Morishita,et al. Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease. , 2010, Molecular bioSystems.
[21] Miles C. Miller,et al. Amyloid Efflux Transporter Expression at the Blood-Brain Barrier Declines in Normal Aging , 2010, Journal of neuropathology and experimental neurology.
[22] I. Heuser,et al. Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing , 2010, Experimental Neurology.
[23] K. Sleegers,et al. Current status on Alzheimer disease molecular genetics: from past, to present, to future , 2010, Human molecular genetics.
[24] Anders Wallin,et al. Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment , 2010, Neurobiology of Aging.
[25] P. Deyn,et al. No correlation between time-linked plasma and CSF Aβ levels , 2009, Neurochemistry International.
[26] F. Grodstein,et al. Ten-year change in plasma amyloid beta levels and late-life cognitive decline. , 2009, Archives of neurology.
[27] L. Buée,et al. Association of plasma amyloid β with risk of dementia , 2009, Neurology.
[28] S. Leurgans,et al. The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.
[29] D. Na,et al. Identification of PSEN1 and APP Gene Mutations in Korean Patients with Early-Onset Alzheimer's Disease , 2008, Journal of Korean medical science.
[30] B. Winblad,et al. The integrity of the blood–brain barrier in Alzheimer’s disease , 2007, Acta neurologica Scandinavica.
[31] R. Petersen,et al. Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease , 2007 .
[32] A. Hofman,et al. Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.
[33] C. Mariani,et al. Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment , 2006, Neurobiology of Aging.
[34] Peter J. Lenting,et al. LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms , 2004, Neuron.
[35] Greg Ward,et al. Interferences in immunoassay. , 2004, The Clinical biochemist. Reviews.
[36] R. Mayeux,et al. Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk , 2003 .
[37] Ann Marie Schmidt,et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.
[38] D. Holtzman,et al. Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease , 2002, Science.
[39] P. Mehta,et al. Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease , 2001, Neuroscience Letters.
[40] D. Holtzman,et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.
[41] H. Wada. Blood-brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio. , 1998, Internal medicine.
[42] N. Inestrosa,et al. Platelets Are the Primary Source of Amyloid β-Peptide in Human Blood , 1995 .
[43] Sang Won Seo,et al. Cognitive profiles and neuropsychiatric symptoms in Korean early-onset Alzheimer's disease patients: a CREDOS study. , 2015, Journal of Alzheimer's disease : JAD.
[44] C. Rowe,et al. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. , 2014, Journal of Alzheimer's Disease.
[45] R. Mayeux,et al. Meta-analysis of plasma amyloid-β levels in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.
[46] C. Rowe,et al. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. , 2010, Journal of Alzheimer's disease : JAD.
[47] J. Buxbaum,et al. APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. , 2010, Journal of Alzheimer's disease : JAD.
[48] Mark R. Wilson,et al. Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. , 2008, Molecular bioSystems.